Table 5 |
|||||
|
Identification of well treated and undertreated patients using the diagnostic code-based and clinical measurement-based approach |
|||||
|
Well treated patients |
Undertreated patients |
||||
|
|
|||||
|
Type of approach |
proportion detected*, % |
N |
Proportion detected**, % |
N |
N of eligible patients per PQI |
|
|
|||||
|
PQI-1 Prescription of any antihypertensive medication in hypertensive T2DM patients |
2070 |
||||
|
|
|||||
|
Reference method |
- |
1687 |
- |
383 |
|
|
Diagnostic code-based, hypertension |
54 (905/1687) |
905 |
21 (79/383) |
79 |
|
|
Measurement-based, SBP ≥140 |
84 (1412/1687) |
1412 |
88 (337/383) |
337 |
|
|
|
|||||
|
PQI-2 Prescription of beta blocker in hypertensive T2DM patients with a history of IHD or MI |
251 |
||||
|
|
|||||
|
Reference method |
- |
159 |
- |
92 |
|
|
Diagnostic code-based, hypertension |
63 (100/159) |
100 |
60 (55/92) |
55 |
|
|
Measurement-based, SBP ≥140 |
79 (125/159) |
125 |
75 (69/92) |
69 |
|
|
|
|||||
|
PQI-3 Prescription of metformin in overweight T2DM patients |
1837 |
||||
|
|
|||||
|
Reference |
- |
1193 |
- |
644 |
|
|
Diagnostic code-based, overweight or obesity |
12 (139/1193) |
139 |
11 (74/644) |
74 |
|
|
Measurement-based, BMI ≥25 |
97 (1154/1193) |
1154 |
95 (613/644) |
613 |
|
|
|
|||||
|
T2DM: Type 2 Diabetes mellitus SBP: Systolic Blood Pressure BMI: Body Mass Index (weight in kilograms divided by height in meters-squared) *Number of treated patients detected through the tested approach divided by the number of treated patients according to the reference method **Number of untreated patients detected through the tested approach divided by the number of untreated patients according to the reference method |
|||||
|
Martirosyan et al. BMC Health Services Research 2010 10:137 doi:10.1186/1472-6963-10-137 |
|||||
